%A Xu,Yilan %A Zhao,Manna %A Han,Yuying %A Zhang,Heng %D 2020 %J Frontiers in Neuroscience %C %F %G English %K GABA inhibitory interneurons,cognitive deficits,Alzheimer ' s disease,amyloid β-protein,PV inhibitory interneurons %Q %R 10.3389/fnins.2020.00660 %W %L %M %P %7 %8 2020-June-30 %9 Review %# %! GABAergic deficits in Alzheimer's disease %* %< %T GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment %U https://www.frontiersin.org/articles/10.3389/fnins.2020.00660 %V 14 %0 JOURNAL ARTICLE %@ 1662-453X %X Alzheimer’s disease (AD) is a neurodegenerative disorder characterized clinically by severe cognitive deficits and pathologically by amyloid plaques, neuronal loss, and neurofibrillary tangles. Abnormal amyloid β-protein (Aβ) deposition in the brain is often thought of as a major initiating factor in AD neuropathology. However, gamma-aminobutyric acid (GABA) inhibitory interneurons are resistant to Aβ deposition, and Aβ decreases synaptic glutamatergic transmission to decrease neural network activity. Furthermore, there is now evidence suggesting that neural network activity is aberrantly increased in AD patients and animal models due to functional deficits in and decreased activity of GABA inhibitory interneurons, contributing to cognitive deficits. Here we describe the roles played by excitatory neurons and GABA inhibitory interneurons in Aβ-induced cognitive deficits and how altered GABA interneurons regulate AD neuropathology. We also comprehensively review recent studies on how GABA interneurons and GABA receptors can be exploited for therapeutic benefit. GABA interneurons are an emerging therapeutic target in AD, with further clinical trials urgently warranted.